ROSCREA, Ireland and FREIBURG, Germany, March 27, 2024 (GLOBE NEWSWIRE) -- Renexxion Ireland Limited (Renexxion), a private biopharmaceutical company committed to delivering innovative drugs to...
ROSCREA, Ireland, and FREIBURG, Germany, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Renexxion Ireland Limited (Renexxion), a private biopharmaceutical company committed to delivering innovative drugs to...
ROSCREA, Ireland, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Renexxion Ireland Limited (Renexxion), a private biopharmaceutical company committed to delivering innovative drugs to patients with high unmet...
ROSCREA, Ireland, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Renexxion Ireland Limited (Renexxion), a private biopharmaceutical company committed to delivering innovative drugs to patients with high unmet...
ROSCREA, Ireland, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Renexxion Ireland Limited (Renexxion), a private biopharmaceutical company committed to delivering innovative drugs to patients with high unmet...
ROSCREA, Ireland, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Renexxion Ireland Limited (Renexxion), a private biopharmaceutical company committed to delivering innovative drugs to patients with high unmet...
LOS ALTOS, Calif., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Renexxion LLC (œRenexxion or the œCompany), a private clinical-stage biopharmaceutical company committed to delivering innovative drugs to...
Renexxion Ireland has announced that the first participant has been treated with its potential best-in-class pan-GI prokinetic, naronapride, in Europe in a Phase IIb trial to treat gastroparesis.
Renexxion is gearing up for two Phase II trials investigating naronapride in patients with cystic fibrosis (CF) and gastrointestinal (GI) dysmotility, says CEO Dr Peter Milner. After the opening of the FDA’s investigational new drug (IND) application earlier this month, Renexxion expects to initiate the studies in Q2 or Q3 this year.